

19104139D

HOUSE JOINT RESOLUTION NO. 662

Offered January 9, 2019

Prefiled January 8, 2019

Directing the Joint Commission on Health Care to study the dispensing of drugs and devices pursuant to pharmacy collaborative practice agreements, standing orders, and statewide protocols in the Commonwealth. Report.

Patrons—Stolle and Lopez

Referred to Committee on Rules

WHEREAS, a pharmacist may only dispense drugs or devices pursuant to a valid prescription issued by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine licensed by the Board of Medicine; a physician assistant licensed by the Board of Medicine who has entered into a practice agreement with a licensed physician or podiatrist; a nurse practitioner licensed jointly by the Boards of Medicine and Nursing who has entered into a practice agreement with a patient care team physician or who meets the requirements for practice without a practice agreement; or a TPA-certified optometrist, or pursuant to a standing order or protocol or in accordance with a collaborative practice agreement; and

WHEREAS, the roles and responsibilities of pharmacists vary depending on the authority pursuant to which they dispense drugs or devices; now, therefore, be it

RESOLVED by the House of Delegates, the Senate concurring, That the Joint Commission on Health Care be directed to study the dispensing of drugs and devices pursuant to pharmacy collaborative practice agreements, standing orders, and statewide protocols in the Commonwealth. In conducting its study, the Joint Commission on Health Care shall review and evaluate laws and regulations governing dispensing and administration of drugs and devices pursuant to pharmacy collaborative practice agreements, standing orders, and statewide protocols; the roles and responsibilities of pharmacists and other health care providers practicing pursuant to pharmacy collaborative practice agreements, standing orders, and statewide protocols; and any changes to such laws or regulations governing the dispensing and administration of drugs and devices pursuant to pharmacy collaborative practice agreements, standing orders, and statewide protocols that would enhance patient access to health care in the Commonwealth. In conducting its study, the Joint Commission on Health Care shall provide for stakeholder input from the Department of Health, the Department of Health Professions, the Medical Society of Virginia, and the Virginia Pharmacists Association.

Technical assistance shall be provided to the Joint Commission on Health Care by the Board of Pharmacy. All agencies of the Commonwealth shall provide assistance to the Joint Commission on Health Care for this study, upon request.

The Joint Commission on Health Care shall complete its meetings for the first year by November 30, 2019, and for the second year by November 30, 2020, and the chairman shall submit to the Division of Legislative Automated Systems an executive summary of its findings and recommendations no later than the first day of the next Regular Session of the General Assembly for each year. Each executive summary shall state whether the Joint Commission on Health Care intends to submit to the General Assembly and the Governor a report of its findings and recommendations for publication as a House or Senate document. The executive summaries and reports shall be submitted as provided in the procedures of the Division of Legislative Automated Systems for the processing of legislative documents and reports and shall be posted on the General Assembly's website.

INTRODUCED

HJ662